Taysha Gene Therapies Inc represents a commitment to advancing gene therapies for people with severe diseases. With a focus on developing transformative treatments, Taysha aims to improve the lives of patients and their families. The company prioritizes scientific innovation and excellence in research, leveraging cutting-edge technologies for the development of potentially life-changing therapies. Taysha Gene Therapies Inc operates under a patient-centric approach, valuing collaboration with key stakeholders to address unmet medical needs. By combining their expertise with a strong corporate philosophy, Taysha is dedicated to delivering innovative gene therapies that can make a significant impact in the field of medicine.

Taysha Gene Therapies Inc is primarily present in the United States.

Some significant milestones achieved by Taysha Gene Therapies Inc include initiating clinical trials for pipeline therapies, securing partnerships with leading institutions and companies, and receiving regulatory designations and approvals. The company has made notable progress in advancing their gene-based treatments for various genetic disorders, such as achieving positive clinical data and reaching key development stages. They have also expanded their research and development efforts and increased collaborations to accelerate the development of innovative therapies. Taysha Gene Therapies Inc's commitment to advancing gene therapies and its noteworthy achievements contribute to its growing reputation within the healthcare industry.

Taysha Gene Therapies Inc is a leading biotechnology company specializing in the development of innovative gene therapies. Founded in 2019, the company is dedicated to transforming the lives of patients with severe genetic disorders by providing effective treatment options. Taysha Gene Therapies Inc focuses on developing cutting-edge therapies that directly address the underlying cause of various diseases. With a team of renowned scientists and experts, the company combines advanced research and development techniques with a patient-centric approach. Through its pioneering efforts, Taysha Gene Therapies Inc aims to deliver hope and improve the quality of life for individuals living with genetic disorders.

The main competitors of Taysha Gene Therapies Inc in the market include companies like Spark Therapeutics, bluebird bio, and CRISPR Therapeutics.

Taysha Gene Therapies Inc is primarily active in the biotechnology and pharmaceutical industries.

Taysha Gene Therapies Inc. operates under a business model focused on developing and commercializing transformative gene therapies for the treatment of rare and monogenic diseases. With a strong emphasis on research and development, Taysha aims to address unmet medical needs by utilizing its proprietary technology platforms. The company's approach involves identifying and evaluating potential gene therapy candidates using advanced genomic testing and translational medicine. Taysha Gene Therapies Inc. is committed to collaborating with patients, physicians, and researchers to bring innovative treatments to individuals affected by genetic disorders.

Taysha Gene Therapies의 P/E 비율은 -3.28입니다.

Taysha Gene Therapies의 P/S 비율은 31.03입니다.

Taysha Gene Therapies에 대한 AlleAktien 품질 점수는 2/10입니다.

예상되는 Taysha Gene Therapies 매출은 8.53 백만 USD입니다.

예상되는 Taysha Gene Therapies 이익은 -80.61 백만 USD입니다.

Taysha Gene Therapies Inc is a biopharmaceutical company specializing in developing therapies for the treatment of rare genetic diseases. The company utilizes an innovative gene therapy platform called "APC" (Adeno-associated Virus) to manufacture its products. Taysha Gene Therapies has several therapies in development, including TSHA-101, TSHA-102, TSHA-118, and TSHA-104. These therapies target the treatment of rare diseases such as GM2 Gangliosidosis, Sanfilippo Syndrome Type A, Rett Syndrome, and Duchenne Muscular Dystrophy. The company's gene therapy platform - "APC" - enables the production of highly effective gene therapies capable of correcting genetic defects at the cellular level. Taysha Gene Therapies' gene therapy platform aims to improve the quality of life for patients with rare genetic diseases and slow down or halt disease progression. Taysha Gene Therapies also collaborates with partner companies to further develop its gene therapy platform and products. The company has established partnerships with UT Southwestern Medical Center and Jennifer S. Li Health Sciences and Technology to enhance its gene therapy platform. Additionally, the company works together with the Muscular Dystrophy Association (MDA) on the development of gene therapy products for the treatment of muscle and nerve disorders. Another important aspect of Taysha Gene Therapies' business model is collaboration with investors to finance the development of its gene therapy platform and products. In 2020, the company received $93 million in funding through a Series B investment round. Overall, Taysha Gene Therapies has developed a business model that aims to develop highly effective gene therapies for the treatment of rare genetic diseases based on the APC platform. The company collaborates with partners and investors to further develop and finance its products. The company strives to improve the quality of life for patients with rare genetic diseases and combat diseases that currently have no treatment options.

Taysha Gene Therapies은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Taysha Gene Therapies의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Taysha Gene Therapies의 ISIN은 US8776191061입니다.

Taysha Gene Therapies의 WKN은 A2QCJL입니다.

Taysha Gene Therapies의 티커는 TSHA입니다.

지난 12개월 동안 Taysha Gene Therapies은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Taysha Gene Therapies은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Taysha Gene Therapies의 현재 배당 수익률은 입니다.

Taysha Gene Therapies은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Taysha Gene Therapies은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Taysha Gene Therapies은 '건강' 섹터에 속합니다.

Taysha Gene Therapies의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Taysha Gene Therapies는 0 USD를 배당금으로 지급했습니다.

Taysha Gene Therapies의 배당금은 USD에 지급됩니다.